US EditionPublished • loading... • Updated
Orforglipron Lowers Hba1c and Weight in Type 2 Diabetes More Effectively than Oral Semaglutide.
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Dallas – The new oral GLP-1 receptor agonist orforglipron lowers HbA1c levels more effectively and leads to greater weight loss in people with type 2 diabetes after one year than semaglutide, the only other available oral drug in this class. These are the findings of the phase III ACHIEVE-3 trial (2026;...), published in The Lancet.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
